<DOC>
	<DOCNO>NCT02623673</DOCNO>
	<brief_summary>Retrospective case series non-randomized , open-label , single-center investigation ( Retina Clinic , São Paulo , Brazil ) patient diagnose macular edema secondary diabetic retinopathy ( DME ) retinal vein occlusion undergo simultaneous treatment intravitreal injection bevacizumab 1.25mg implant dexamethasone 0.7mg .</brief_summary>
	<brief_title>Simultaneous Therapy With Intravitreal Dexamethasone Implant Bevacizumab Treatment Macular Edema</brief_title>
	<detailed_description>This retrospective case series non-randomized , open-label , single-center investigation ( Retina Clinic , São Paulo , Brazil ) approve Institutional Review Board Hospital Oftalmológico de Sorocaba/SP , adhere tenet Declaration Helsinki . Were include patient old 18 year , treat April 2014 July 2015 , diagnose macular edema secondary diabetic retinopathy ( DME ) retinal vein occlusion undergo simultaneous treatment intravitreal injection bevacizumab 1.25mg ( Avastin ; Genentech , South San Francisco , CA ) intravitreal implant dexamethasone 0.7mg ( Ozurdex ; Allergan , Inc , Irvine , CA ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>central macular thickness &gt; 300 µm optical coherence tomography ( OCT ) macular edema secondary diabetic retinopathy ( DME ) retinal vein occlusion intravitreal antiVEGF within 6 week treatment laser intravitreal corticosteroid within 3 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>